Stevanato Group reported strong second-quarter 2025 results, with revenue increasing 8% year-over-year to €280.0 million, or 10% on a constant currency basis. This growth was primarily driven by a 10% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, which reached €243.5 million.
High-value solutions (HVS) revenue grew to €116.8 million, representing 42% of total revenue, led by strong demand for high-value syringes and increased production capacity in Latina and Fishers. The consolidated gross profit margin expanded by 210 basis points to 28.1%, with the BDS segment's gross profit margin rising 350 basis points to 31.2%.
The company reaffirmed its fiscal year 2025 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS, indicating confidence in its strategic trajectory. Despite a 2% decline in the Engineering segment's revenue and negative operating profit margin due to an unfavorable project mix, the majority of legacy projects were completed in the first half of 2025. Stevanato Group reported negative free cash flow of €13 million, a significant improvement from the prior year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.